Paul Stellato was named Chief Financial Officer of Zimmer Biomet Holdings, Inc., succeeding Suketu Upadhyay. As of November 6, 2026, Zimmer Biomet Holdings, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 28, 2026 to September 8, 2026, naming 1 appointment and 1 departure (Form 8-K, April 28, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Zimmer Biomet Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Zimmer Biomet Holdings, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-28 to 2026-09-08. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Zimmer Biomet Holdings, Inc. files it.
Also on the record for Zimmer Biomet Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 13, 2026 | Stake report, Schedule 13G/A, by Dodge & Cox | 12.5% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G, by Capital International Investors | 6.4% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 4.1% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 7.54% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by HARRIS ASSOCIATES L P | 6.2% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13G/A, by Dodge & Cox | 11.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Zimmer Biomet Holdings, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Zimmer Biomet Holdings, Inc. and the records around it.
Zimmer Biomet Holdings, Inc. elsewhere on the record
Companies that share a holder
- HARRIS ASSOCIATES L P also filed stake reports on 19 other companies: Corebridge Financial, Inc. (May 2026), ICON plc (May 2026), Lithia Motors, Inc. (May 2026)
- Dodge & Cox also filed stake reports on 36 other companies: Charter Communications, Inc. (Aug 2026), SUN COMMUNITIES, INC (Aug 2026), TransUnion (Jun 2026)
- Capital International Investors also filed stake reports on 96 other companies: Aurora Innovation, Inc. (Nov 2026), Arxis, Inc. (Aug 2026), Astronics Corp. (Aug 2026)
Watch Zimmer Biomet Holdings, Inc.
Get an email when Zimmer Biomet Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Zimmer Biomet Holdings, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Zimmer Biomet Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Zimmer Biomet Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-08 | Reported | not named in the filing | 8-K, 2026-09-08 | ||
| 2026-04-28 | Out | Chief Financial Officer | 2026-04-28 | 8-K, 2026-04-28 | |
| 2026-04-28 | In | Chief Financial Officer | 8-K, 2026-04-28 |
Who leads Zimmer Biomet Holdings, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Suketu Upadhyay, departure reported, effective 2026-04-28 (filed 2026-04-28). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Zimmer Biomet Holdings, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Zimmer Biomet Holdings, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Zimmer Biomet Holdings, Inc.Every change, in the filing's words
Reported
Mr. Thornal will be departing from the Company, effective on September 30, 2026.
- On September 8, 2026, Zimmer Biomet Holdings, Inc. (the "Company") notified Kevin Thornal, Group President, Global Businesses and the Americas, that his position is being restructured.
- Mr. Thornal will be eligible for severance benefits under the Company's Restated Executive Severance Plan, as amended (the "Severance Plan").
- Pursuant to the Severance Plan, Mr. Thornal will receive benefits, including a lump sum amount equal to the sum of twelve months of his annual base salary plus target annual bonus, plus twelve months of his current monthly COBRA premiums.
- His right to receive such severance payments and benefits is conditioned upon his executing and not revoking a general release in favor of the Company.
Departing: Suketu Upadhyay, Chief Financial Officer, effective 2026-04-28
On April 22, 2026, Suketu Upadhyay informed Zimmer Biomet Holdings, Inc. (the "Company") of his intention to resign from the position of Chief Financial Officer and Executive Vice President - Finance, Operations and Supply Chain of the Company, effective as of April 28, 2026, to pursue a new professional opportunity.
Appointed: Paul Stellato, Chief Financial Officer
In connection with Mr. Upadhyay's departure, Paul Stellato, Vice President, Controller and Chief Accounting Officer, has been appointed to act, along with continuing to serve in his current role, as the Company's interim Chief Financial Officer, effective upon Mr. Upadhyay's departure, until a permanent successor is named.
- Mr. Upadhyay's departure is not the result of any disagreement with the Company on any matter relating to its financial statements, internal control over financial reporting, operations, policies or practices.
- In this role, Mr. Stellato will serve as the Company's principal financial officer and will continue to serve as the Company's principal accounting officer.
- The Company has a search underway to identify a permanent Chief Financial Officer.
- Mr. Stellato, age 51, has served as the Vice President, Controller and Chief Accounting Officer at the Company since May 2022.
- In this role, he oversees the Company's global controllership and accounting functions as well as leading the financial planning and analysis function.
- Prior to his current role, Mr. Stellato served as Vice President Finance, Global Business Services from March 2019 through April 2022 for Xylem Inc. ("Xylem"), a global provider of water technology products and services.
- He joined Xylem upon its spinoff from ITT Corporation ("ITT") in October 2011 and served as Xylem's Vice President Finance, Financial Planning and Analysis through August 2017.
- He was promoted to Vice President, Controller and Chief Accounting Officer in August 2017 after serving as Interim Corporate Controller starting in August 2016, and became Vice President Finance, Global Business Services in March 2019.
Tools for this story
Each opens in a new tab, filled in for Zimmer Biomet Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.